Steatosis–Associated Fibrosis Estimator (SAFE) Score
Nonproprietary primary-care score designed to detect clinically significant liver fibrosis (>=F2) using routine clinical and metabolic parameters.
While FIB-4 was originally built to catch advanced scarring (F3–F4), the newer SAFE score was specifically designed in MASLD populations to catch moderate-or-worse scarring (F2 and above) earlier in primary care. A SAFE score below 0 helps rule out clinically significant fibrosis, while a score of 100 or higher makes F2+ scarring likely and supports specialist evaluation.
What Is the SAFE Score?
- A nonproprietary score combining 7 routine clinical and laboratory inputs (age, BMI, diabetes status, AST, ALT, platelet count, and globulins [total protein minus albumin])1
- Estimates the likelihood of clinically significant liver fibrosis (≥F2) in patients with suspected liver disease1,2
Use in MASLD/MASH Care
- Supports risk stratification in primary care settings, helping determine which patients can be safely monitored in primary care and which warrant referral to specialist care1
How Is It Measured?
+ (62.85 × diabetes [0 if absent, 1 if present])
+ (154.85 × Ln(AST)) – (58.23 × Ln(ALT))
+ (195.48 × Ln(globulins, g/dL))
– (141.61 × Ln(platelets, 109/L)) – 75
- It is calculated using the following formula available online1
Strengths
- The SAFE score can predict fibrosis across all patient groups regardless of race/ethnicity or diabetes status2
Limitations
- Unclear diagnostic performance in populations with low BMI (<25 kg/m2) or Asian populations due to limited data1
Interactive SAFE Score Calculator (≥F2 Fibrosis Screen)
100% Private • Runs in BrowserComputes the logarithmic 7-variable SAFE formula (Sripongpun et al., Hepatology 2023). Tip: if your CMP does not print Globulin directly, subtract Albumin from Total Protein (e.g. Total Protein 7.1 − Albumin 4.3 = 2.8 g/dL).
Published Cutoff Values for Fibrosis Staging Using the SAFE Score1,3
| Clinical Tier | SAFE Score | Sensitivity,a % | Specificity,b % |
|---|---|---|---|
| Low Risk (Rule out ≥F2) | <0 | 77 | 58 |
| Intermediate Risk (Proceed to VCTE or ELF™) | 0 to <100 | Indeterminate zone — confirm fibrosis stage with second-line elastography or serum NIT1 | |
| High Risk (Rule in ≥F2) | ≥100 | 43 | 88 |